DEFA14A
Table of Contents

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 14A

(Rule 14a-101)

INFORMATION REQUIRED IN PROXY STATEMENT

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

 

 

Filed by the Registrant  ☒

Filed by a party other than the Registrant  ☐

Check the appropriate box:

 

Preliminary Proxy Statement

 

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

 

Definitive Proxy Statement

 

Definitive Additional Materials

 

Soliciting Material Pursuant to §240.14a-12

Agios Pharmaceuticals, Inc.

(Name of Registrant as Specified in its Charter)

Not applicable.

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

 

No fee required.

 

Fee paid previously with preliminary materials.

 

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

 

 

 


Table of Contents

LOGO

P.O. BOX 8016, CARY, NC 27512-9903

Agios Pharmaceuticals, Inc.

Important Notice Regarding the Availability

of Proxy Materials

for the

Stockholders Meeting to be held on

June 13, 2023

For Stockholders of record as of April 17, 2023

This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting.

To view the proxy materials, and to register to attend the virtual annual meeting, go to: www.proxydocs.com/AGIO

To vote your proxy while visiting this site, you will need the 12 digit control number in the box below.

Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet. We have chosen to use this procedure for our annual meeting.

 

 

        

 

LOGO  

 

For a convenient way to view proxy materials and VOTE go to www.proxydocs.com/AGIO

 

       LOGO  
  Have the 12 digit control number located in the shaded box above available when you access the website and follow the instructions.
  Proxy Materials Available to View or Receive:
 

Annual Report and Proxy Statement

 

 

If you want to receive a paper or e-mail copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year’s meeting, you must make this request on or before June 02, 2023.

    

To order paper materials, use one of the following methods.

 

LOGO

 

INTERNET

www.investorelections.com/AGIO

   

 

LOGO

 

TELEPHONE

(866) 648-8133

   

 

LOGO

* E-MAIL

paper@investorelections.com

 

When requesting via the Internet or telephone you will need the 12 digit control number located in the shaded box above.

  * If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located above) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material.

 

 

Agios Pharmaceuticals, Inc.

 

Meeting Type:   Annual Meeting of Stockholders

Date:  Tuesday, June 13, 2023

Time:  9:00 AM, Eastern Time

Place:  Annual Meeting to be held live via the Internet

     please visit www.proxydocs.com/AGIO for more details.

 

You must register to attend the meeting online and/or participate at www.proxydocs.com/AGIO

 

SEE REVERSE FOR FULL AGENDA

 


Table of Contents

Agios Pharmaceuticals, Inc.

Annual Meeting of Stockholders

THE BOARD OF DIRECTORS RECOMMENDS A VOTE:

FOR EACH OF THE NOMINEES LISTED IN PROPOSAL 1, AND FOR PROPOSALS 2, 3, AND 4.

PROPOSAL

 

1.

To elect each of the three Class I director nominees set forth in the Proxy Statement for three-year terms expiring at the 2026 annual meeting of stockholders.

1.01 Rahul Ballal

1.02 Brian Goff

1.03 Cynthia Smith

 

2.

To vote, on an advisory basis, to approve named executive officer compensation.

 

3.

To approve the Agios Pharmaceuticals, Inc. 2023 Stock Incentive Plan.

 

4.

To ratify the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023.

Note: The proxies are authorized to vote, in their discretion, upon such other business that may properly come before the Annual Meeting or any adjournment or postponement thereof.

Attending and Voting Online During the Meeting: The annual meeting will be a virtual meeting. You will need your 12 digit control number set forth in the box above in order to attend the meeting and vote online. To participate in the annual meeting, you must register at www.proxydocs.com/AGIO prior to the deadline of June 11, 2023 at 5:00 p.m. Eastern Time. Upon completing your registration, you will receive further instructions via email, including your unique links that will allow you access to the meeting and will also permit you to submit questions. Please be sure to follow instructions found on your proxy card, this notice and subsequent instructions that will be delivered to you via email.